Prosperity Wealth Management Inc. Purchases Shares of 3,300 BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Prosperity Wealth Management Inc. acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,300 shares of the company's stock, valued at approximately $300,000.

A number of other institutional investors have also recently bought and sold shares of the business. TB Alternative Assets Ltd. bought a new position in BioNTech in the 1st quarter valued at $3,551,000. GAMMA Investing LLC lifted its position in shares of BioNTech by 5,710.8% during the 1st quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock valued at $4,884,000 after buying an additional 52,711 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in shares of BioNTech during the 4th quarter valued at $238,000. Probity Advisors Inc. increased its holdings in BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after acquiring an additional 154 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in BioNTech in the 4th quarter valued at about $570,000. Institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

BNTX has been the subject of a number of research reports. HC Wainwright cut their target price on shares of BioNTech from $145.00 to $138.00 and set a "buy" rating for the company in a research report on Monday. Citigroup reaffirmed a "buy" rating and issued a $140.00 price objective (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Leerink Partners set a $112.00 price objective on shares of BioNTech in a research note on Monday, June 2nd. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Finally, Truist Financial reaffirmed a "buy" rating and issued a $155.00 price target (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $137.86.

BioNTech Price Performance

Shares of NASDAQ:BNTX traded down $0.57 on Thursday, hitting $104.40. The company's stock had a trading volume of 894,938 shares, compared to its average volume of 949,716. The company has a 50-day simple moving average of $101.79 and a 200 day simple moving average of $107.84. BioNTech SE Sponsored ADR has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a market capitalization of $25.10 billion, a PE ratio of -30.71 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.